Abstract | BACKGROUND: RESULTS: In this study, we developed a MCPyV ST-expressing tumor cell line from B16 mouse melanoma cells. We then utilized this ST-expressing tumor cell line to test the efficacy of a DNA vaccine encoding ST. In ST-expressing tumor-bearing mice, this vaccine, pcDNA3-MCC/ST, generated a significant number of ST antigenic peptide-specific CD8+ T cells and experienced markedly enhanced survival compared to mice vaccinated with empty vector. CONCLUSIONS: The formation of an effective vaccine against MCPyV has the potential to advance the field of MCC therapy and may contribute to the control of this severe malignancy through immunotherapy. Both of the innovative technologies presented here provide opportunities to develop and test MCPyV-targeted therapies for the control of Merkel cell carcinoma.
|
Authors | Bianca Gomez, Liangmei He, Ya Chea Tsai, T-C Wu, Raphael P Viscidi, Chien-Fu Hung |
Journal | Cell & bioscience
(Cell Biosci)
Vol. 3
Issue 1
Pg. 29
(Jul 15 2013)
ISSN: 2045-3701 [Print] England |
PMID | 23856459
(Publication Type: Journal Article)
|